Notman Donald 4

What Happened Donald Notman, Chief Operating Officer of Ocular Therapeutix, sold a total of 11,490 shares of OCUL stock in two open-market transactions to cover tax withholding tied to restricted stock unit (RSU) vestings. On 2026-02-02 he disposed of 5,455 shares at a weighted average price of $9.14 for proceeds of $49,859; on 2026-02-04 he disposed of 6,035 shares at a weighted average price of $8.54 for proceeds of $51,539. Total proceeds were about $101,398. The sales were non-discretionary sell-to-cover transactions (not open-market directional trades by the insider).

Key Details

• Transaction dates and prices:
  • 2026-02-02: 5,455 shares sold, weighted avg $9.14 (price range $9.0565–$9.3217) — $49,859 (F1, F2)
  • 2026-02-04: 6,035 shares sold, weighted avg $8.54 (price range $8.4377–$8.6769) — $51,539 (F3, F4)
• Reason: Sales executed under a durable automatic sales instruction (sell-to-cover) to satisfy tax withholding related to RSU vesting (vest dates Jan 30, 2026 and Feb 3, 2026). The filing states these were not discretionary trades.
• Additional note: The filer offers to provide detailed per-price breakdowns on request (per footnotes).
• Shares owned after the transactions: not specified in the provided filing.
• Filing date: Form 4 filed 2026-02-04 covering the above transactions; no late-filing indication provided in the materials supplied.

Context

• These transactions are routine tax-withholding "sell-to-cover" dispositions of vested RSUs (transaction code F), not purchases or voluntary sales intended as a market signal. For retail investors, such sales generally do not by themselves indicate insider sentiment about company prospects.